The well-studied NF-κB signaling system is a key mediator of the inflammatory response. Large-scale sequencing studies in ...

During cell-to-cell spread, HIV-1 protease activity triggers CARD8 inflammasome activation and IL-1β release from macrophages, which may contribute to inflammation and chronic immune activation.

The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...

Global Oral Antiviral Market is valued approximately USD 36.7 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 2.10% over the forecast period 2024-2032. Read the ...

Exposure to nucleoside reverse transcriptase inhibitors (NRTIs), which treat HIV and hepatitis B and inhibit inflammasome activation, is associated with a significantly lower incidence of Alzheimer ...

At the Pink Triangle Services board meeting in July 1985, Deeprose proposed that an AIDS Committee of Ottawa be created to ...

not the other HIV drugs, including protease inhibitors," the doctor said. "I think this is convincing preliminary evidence that warrants further study," Siegel added. "It is very possible that ...

The pilot open-label randomized clinical trial demonstrated that the use of the drug in addition to protease inhibitor (PI)-based antiretroviral therapy (ART), a common HIV medication, can safely ...

But unlike the many, more common antiviral drugs that can be used to fight against viruses such as flus, protease inhibitors can also be used to help combat HIV (human immunodeficiency virus).

may be mitigated or reversed over time by switching to protease inhibitor-based ART. For patients with HIV infection who experience weight gain on integrase strand transfer inhibitor (INSTI)-based ...

Here is a list of FDA-approved nucleoside reverse transcriptase inhibitors and the year they were approved: Protease inhibitors are drugs used to treat HIV, along with viral infections such as ...

Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.